By Kamal Choudhury and Mariam Sunny Nov 6 (Reuters) – Moderna lifted its full-year revenue forecast on Friday after strong international COVID-19 vaccine demand and payments from partnerships helped the biotech swing to profit in the third quarter, sending its shares up over 10%. The rally builds on a blockbuster year for Moderna, whose stock […]
Health
Moderna lifts annual revenue forecast on strong COVID vaccine demand overseas
Audio By Carbonatix
By Kamal Choudhury and Mariam Sunny
Nov 6 (Reuters) – Moderna lifted its full-year revenue forecast on Friday after strong international COVID-19 vaccine demand and payments from partnerships helped the biotech swing to profit in the third quarter, sending its shares up over 10%.
The rally builds on a blockbuster year for Moderna, whose stock has skyrocketed more than eightfold, largely fueled by encouraging late-stage data from its personalized cancer vaccine candidate developed with Merck.
The upbeat results serve as a “cherry on top” of the company’s recent cancer vaccine breakthrough, said Evercore ISI analyst Cory Kasimov.
Detailed late-stage data last month showed the cancer vaccine, intismeran autogene, combined with Keytruda cut melanoma recurrence or death by 42%.
Moderna said it was working to ensure that the US marketing application for intismeran was submitted this year.
The companies target a commercial launch in 2027.
“We think we’re at the very beginning of a scientific revolution, and we’re excited to be in the lead,” Stephen Hoge, president of Moderna, said on a call with analysts.
Analysts said investors were looking for greater clarity on the next steps for intismeran, with the lack of updates briefly weighing on the stock before shares recovered.
Investors remain more focused on the oncology pipeline and upcoming data readouts than on a near-term earnings beat, said William Blair analyst Myles Minter.
Moderna expects total revenue to grow 15% to 25% in 2026, above its previous forecast of up to 10% growth.
The company said it will not test its experimental norovirus vaccine in an additional cohort this season, reversing earlier plans to expand the study after it failed to meet the statistical threshold for early success in an interim analysis.
“It appears that Moderna is raising the bar for R&D, keeping costs constrained by no longer entertaining a new season for Norovirus,” Bernstein analysts said.
Its third-quarter revenue came in at $1.3 billion, topping analysts’ expectations of $885.1 million, according to data compiled by LSEG.
Moderna earned a net profit of $162 million, compared with a net loss of about $200 million a year earlier.
(Reporting by Kamal Choudhury and Mariam Sunny in Bengaluru; Editing by Shinjini Ganguli)

